N6-Methyladenosine (m6A) is a key eukaryotic mRNA modification regulating mRNA fate. Our service uses advanced synthesis and m6A mapping (MiClip/MeRIP-seq) to aid mRNA therapeutic design and target identification.
Creative Biolabs delivers custom-modified mRNA with tunable stability, plus single-nucleotide resolution data, translating m6A biology into actionable leads to accelerate your pipeline.
Discover How We Can Help - Request a Consultation
Fig.1 The localization, formation, identification, and deletion of m6A.1,3
The functional significance of m6A is based on its dynamic regulation by three groups of proteins, which collectively form a sophisticated signaling cascade:
The m6A mark is typically installed on adenine within the conserved DRACH motif (where D = A, G or U; R = A or G; H = A, C or U).
The enzymatic and reversible nature of the m6A machinery offers unique therapeutic advantages:
Fig.2 The alterations in total m6A levels and the expression of m6A-regulating proteins in individuals diagnosed with PD.2,3
Our comprehensive and detailed workflow ensures successful and high-quality outcomes, providing clear accountability and milestones for every project.
| Phase | Key Steps Involved |
|---|---|
| Project Initiation & Design | Required Starting Materials: Clients typically provide the target mRNA sequence, specific m6A site preference (if known), and details regarding the desired functional outcome (e.g., increased stability, modulated translation). |
| Custom Synthesis & Modification | The target mRNA is synthesized using our advanced IVT platforms. Specific m6A marks are introduced chemically or enzymatically, based on client specifications and functional goals (e.g., site-specific m6A incorporation). |
| Quality Control (QC) & Validation | Full-spectrum QC is performed, including Cap and Poly(A) tail integrity analysis, and confirmation of m6A incorporation and purity via techniques like HPLC and Mass Spectrometry. |
| Mechanistic Functional Analysis | m6A site mapping is conducted using high-resolution technologies (MiClip or MeRIP-seq). Functional assays assess the impact of the modification on mRNA stability (half-life) and protein translation efficiency in relevant cell lines. |
| Data Interpretation & Reporting | Expert analysis of all experimental data is conducted, providing clear conclusions on the m6A mechanism and therapeutic potential. |
Estimated Timeframe: The typical timeframe for this service ranges from 6 to 12 weeks, depending on the complexity of the custom modification, the size of the target transcript, and the depth of functional analysis requested.
As an excellent seller and technical partner, Creative Biolabs is committed to delivering unparalleled precision and strategic depth in the epitranscriptomic field. We offer fully customized service packages to meet the demanding requirements of both fundamental research and late-stage drug development.
Custom N6-Methyladenosine Incorporation
N6-Methyladenosine incorporation at any specific, client-defined site on your mRNA transcript, supporting customized functional design.
Ultra-High-Resolution m6A Mapping
One-stop analysis service utilizing proprietary MiClip and SCARLET technologies for single-nucleotide precision in target validation.
Comprehensive Target Screening
Functional assays to screen inhibitors against all three classes of m6A regulators: Writers (METTL3/14), Erasers (FTO/ALKBH5), and Readers (YTHDF family).
Optimized mRNA Performance
Customizable functional endpoints, including fine-tuning mRNA half-life, protein translation efficiency, and modulating splicing regulation for optimal therapeutic effect.
Rationally Designed Constructs
Optimization of m6A placement and codon usage to facilitate maximal expression in selected host systems.
Expert Disease Consultation
Epitranscriptomic consultation leveraging extensive internal and published data in high-value areas like oncology and neurodegeneration (e.g., Parkinson's Disease).
Rigorous Quality Control
High-standard quality control tools (HPLC, Mass Spectrometry) used to quantify and evaluate the purity and site-specificity of m6A modification, ensuring superior documentation quality.
A: Yes. We do comprehensive, unbiased m6A mapping (MeRIP-seq/MiClip) in your cell/tissue model to identify novel sites, providing data to advance your project from hypothesis to validation.
A: Unlike pseudouridine (enhances stability, reduces immunogenicity), m6A acts as a post-transcriptional switch. It engages Reader proteins to tune mRNA fate, enabling nuanced control over expression kinetics.
A: Yes. Rapid m6A-mediated target mRNA degradation may lower protein levels. We offer epitranscriptomic audits to map m6A status and identify responsible regulators, revealing potential targets.
A: Yes. We quantify m6A regulator (e.g., METTL14, FTO) expression in patient samples via qPCR/sequencing, helping identify sensitive diagnostic/prognostic markers linked to disease progression.
A: Ensure site-specificity—non-specific m6A causes unpredictable transcriptome changes. We use rational design and HPLC/Mass Spectrometry QC to place m6A exactly as intended.
Creative Biolabs' N6-Methyladenosine Modification Service is your gateway to the next generation of precision therapeutics. We empower clients to move beyond standard genomic approaches by providing the tools and expertise to synthesize custom m6A-modified mRNA, validate epitranscriptomic targets, and develop potent inhibitors against the m6A Writers, Erasers, and Readers that drive disease.
Contact Our Team for More Information and to Discuss Your Project| Cat. No | Product Name | Promoter |
|---|---|---|
| CAT#: GTVCR-WQ001MR | IVTScrip™ pT7-mRNA-EGFP Vector | T7 |
| CAT#: GTVCR-WQ002MR | IVTScrip™ pT7-VEE-mRNA-EGFP Vector | T7 |
| CAT#: GTVCR-WQ003MR | IVTScrip™ pT7-VEE-mRNA-FLuc Vector | T7 |
| CAT#: GTVCR-WQ87MR | IVTScrip™ pT7-VEE-mRNA-Anti-SELP, 42-89-glycoprotein Vector | T7 |
| Cat. No | Product Name | Type |
|---|---|---|
| CAT#: GTTS-WQ001MR) | IVTScrip™ mRNA-EGFP (Cap 1, 30 nt-poly(A)) | Reporter Gene |
| CAT#: GTTS-WK18036MR | IVTScrip™ mRNA-Human AIMP2, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) | Enzyme mRNA |
| (CAT#: GTTS-WQ004MR) | IVTScrip™ mRNA-Fluc (Cap 1, 30 nt-poly(A)) | Reporter Gene |
| (CAT#: GTTS-WQ009MR) | IVTScrip™ mRNA-β gal (Cap 1, 30 nt-poly(A)) | Reporter Gene |
References
